InnoSIGN

Sole Financial Adviser

Kempen & Co acted as exclusive financial adviser in the transaction related to the spin-out and capital increase of InnoSIGN

InnoSIGN, a promising digital health scale-up, has successfully spun out of Philips and completed a Series A capital increase with a consortium of high quality US and European investors
Investors in the round include Casdin Capital, Life Sciences Angels, Thuja Capital and BOM. Philips owns a minority stake in the newly formed company
The proceeds of the round will be used to finance the spin-out from Philips and implement InnoSIGN’s ambitious growth plans to revolutionize precision medicine
Kempen & Co acted as exclusive financial adviser in this transaction
The transaction is a further testament to the joint effort of the Kempen & Co’s Life Sciences sector and Tech sector teams. It also underpins Kempen & Co’s strong position in M&A and fundraise advisory for growth companies
Since 2020, Kempen & Co advised on more than 95 transactions across 16 countries, representing a total deal value of €30 billion

InnoSIGN commercialises its proprietary mRNA-based OncoSIGNal pathway activity profiling technology, revolutionizing precision medicine by obtaining more insight into the mechanisms of disease
The company leverages a combination of proprietary mRNA-based signalling pathway tests, a unique database with over 100 thousand pathway activity profiles, and advanced cloud-based analytics software
InnoSIGN is headquartered in the US and has R&D operations located at the High Tech Campus in Eindhoven, the Netherlands